Tenofovir Alafenamide (GS-7340)

Description: Tenofovir Alafenamide (formerly also known as TAF and GS-7340) is a novel prodrug of tenofovir, which is a potent reverse transcriptase inhibitor nucleotide reverse transcriptase inhibitor (NRTIs), it is used for the treatment of HIV and Hepatitis B. By blocking reverse transcriptase, Tenofovir Alafenamide prevent HIV from multiplying and can reduce the amount of HIV in the body. Tenofovir alafenamide is a prodrug that it is inactive in the parent form, and has to be converted to tenofovir diphosphate (TFV-DP) in vivo.

References: Nucleosides Nucleotides Nucleic Acids. 2001; 20:1085-90; Antimicrob Agents Chemother. 2005; 49:1898-906.

Related CAS#: 147127-20-6 (Tenofovir); 202138-50-9 (fumarate); 206184-49-8 (hydrate); 206184-49-8 (hydrate); 1571075-19-8 (aspartate); 201341-05-1 Tenofovir dsoproxil); 1236287-04-9 (Tenofovir maleate); 1392275-56-7 (Tenofovir alafenamide hemifumarate); 379270-38-9 (Tenofovir alafenamide fumarate); 1464851-21-5 (Z)-9-Propenyladenine; (Z)-Mutagenic Impurity of Tenofovir Disoproxil; 1446486-33-4 9-Propenyladenine; Mutagenic Impurity of Tenofovir Disoproxil; Tenofovir Impurity 2